Impact of canagliflozin combined with metformin therapy on reducing cardiovascular risk in type 2 diabetes patients.

ABSTRACT:

Purpose

To investigate the impact and safety of canagliflozin combined with metformin on reducing cardiovascular risk in patients with type 2 diabetes mellitus (T2DM).

Methods

A total of 258 patients with T2DM admitted to our hospital from March 2021 to March 2022 were selected and divided into a control group and an observation group using a random number table. The control group received metformin combined with a placebo, while the observation group received canagliflozin combined with metformin therapy. All patients received drug treatment for 52 weeks. The primary endpoint of the study was major adverse cardiovascular events (MACE), including myocardial infarction, ischemic stroke, and cardiovascular death. Other study parameters included safety after medication, severe

SUBMITTER: Chen X 

PROVIDER: S-EPMC11330023 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature